Pacira BioSciences, Inc. has confirmed its merger with Viatris Inc., a move that will see Pacira become a wholly owned subsidiary of Viatris. The merger is significant as it marks a strategic consolidation in the pharmaceutical preparations sector, potentially enhancing operational efficiencies and market reach for both companies.

In the filing dated October 30, 2026, Pacira outlined the terms of the merger, which includes an offer price of $36.50 per share for its outstanding common stock. The merger agreement was initially signed on October 8, 2026, and is expected to close by November 16, 2026, subject to regulatory approvals and other customary conditions.

Background

Pacira BioSciences, Inc. operates in the pharmaceutical preparations industry, specifically focusing on the development and commercialization of innovative non-opioid pain management solutions. The company is listed on the Nasdaq under the ticker symbol PCRX and is categorized as a large accelerated filer. Its principal office is located in Brisbane, California.

What the Filing Says

The filing indicates that the merger will be executed without a stockholder vote, in accordance with Delaware law. It states, "The Merger will be governed by Section 251(h) of the DGCL and effected without a meeting of Pacira’s stockholders and without a vote on the adoption of the Merger Agreement by Pacira’s stockholders." This approach is designed to streamline the merger process.

Impact

This merger may significantly impact Pacira's shareholders, employees, and the broader pharmaceutical industry. By joining forces with Viatris, Pacira aims to leverage Viatris’ extensive resources and distribution networks, potentially leading to enhanced product offerings and improved market competitiveness.

What's Next

The next steps involve the completion of the merger process, anticipated to finalize by the expiration date of the tender offer on November 16, 2026. The filing does not specify any further actions required from shareholders at this time.